Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France

Objective. To describe real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy in the United Kingdom, Spain, Germany, and France. Methods. Physicians completed a web-based medical record abstraction for adult patients with advanced STS (other than Kaposi’s sarcoma or gastrointestinal stromal tumor) who received ≥1 line of systemic therapy. Clinical characteristics, treatments, tumor responses, and mortality data were recorded. Results. A total of 130 physicians provided data for 807 patients. Patients’ mean age at advanced STS diagnosis was 57.1 (±12.3) years; 59% were male. The most commonly identified histologic categories were leiomyosarcoma (28%), liposarcoma (13%), and rhabdomyosarcoma (11%). Overall, 57% of patients received only 1 line of therapy, 32% received 2 lines of therapy, and 11% received ≥3 lines of therapy. The most common first-line regimens were doxorubicin alone (41%), doxorubicin plus ifosfamide (19%), docetaxel plus gemcitabine (9%), paclitaxel alone (4%), and ifosfamide (4%). Median overall survival from start of treatment was estimated to be 17.6 months (95% confidence interval, 15.6–19.0 months). Conclusions. In real-world clinical practice, advanced STS is most commonly treated with older therapies in the United Kingdom, Spain, Germany, and France. New therapies that improve overall survival in advanced STS are needed.

Download Full-text

Real-World Treatment Patterns and Outcomes for Patients with Advanced Soft Tissue Sarcoma Receiving Systemic Therapy in The United Kingdom

Value in Health ◽

10.1016/j.jval.2016.09.2310 ◽

2016 ◽

Vol 19 (7) ◽

pp. A751 ◽

Cited By ~ 3

Author(s):

DS Mytelka ◽

M Lorenzo ◽

D Stafkey-Mailey ◽

Y D'yachkova ◽

SP Nagar ◽

...

Keyword(s):

United Kingdom ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Real World ◽

Systemic Therapy ◽

Treatment Patterns ◽

Advanced Soft Tissue Sarcoma ◽

The United Kingdom

Download Full-text

Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France

Sarcoma ◽

10.1155/2018/2020591 ◽

2018 ◽

Vol 2018 ◽

pp. 1-13

Author(s):

Daniel S. Mytelka ◽

Saurabh P. Nagar ◽

Yulia D’yachkova ◽

Elizabeth M. La ◽

James A. Kaye ◽

...

Keyword(s):

Health Care ◽

United Kingdom ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Resource Utilization ◽

Health Care Resource ◽

Adult Patients ◽

Advanced Soft Tissue Sarcoma ◽

Health Care Resource Utilization ◽

The United Kingdom

Objective. To describe health care resource utilization and costs for patients with advanced soft tissue sarcoma (STS) in the United Kingdom (UK), Spain, Germany, and France. Methods. Physicians abstracted data for adult patients with a diagnosis of advanced STS (other than Kaposi’s sarcoma or gastrointestinal stromal tumor) who received ≥1 lines of systemic therapy. Health care resource utilization related to advanced STS treatment was recorded; associated costs were estimated by applying unit costs. Results. A total of 130 physicians provided data for 807 patients (UK: 199; Spain: 203; Germany: 204; and France: 201). The site of care during active treatment varied based on differences in the health care systems of these four countries. Total mean per-patient health care cost in the UK was £19,457; in Spain, €26,814; in Germany, €20,468; and in France, €24,368. Advanced STS-related systemic treatment costs were driven primarily by drug acquisition and administration costs. Treatment-related costs increased during later lines of therapy for all countries except France, where they decreased after first-line therapy. Pain control and antiemetics were the most common supportive care medications. Conclusions. This study provides real-world data on resource utilization and estimated costs in advanced STS and could inform policymakers about treatment burden.

Download Full-text

PCN500 REAL-WORLD TREATMENT PATTERNS AND OUTCOMES FOR PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA RECEIVING SYSTEMIC THERAPY IN BRAZIL

Value in Health ◽

10.1016/j.jval.2019.09.692 ◽

2019 ◽

Vol 22 ◽

pp. S534-S535

Author(s):

A.C. Melo ◽

P.X. Santi ◽

D.L. Nunes ◽

S.B. Aleixo ◽

C.L. Martins ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Real World ◽

Systemic Therapy ◽

Treatment Patterns ◽

Advanced Soft Tissue Sarcoma

Download Full-text

Real-World Outcomes of Advanced Soft Tissue Sarcoma Patients Treated with Pazopanib

Sarcoma Research - International ◽

10.26420/sarcomaresint.2021.1047 ◽

2021 ◽

Vol 6 (1) ◽

Author(s):

Fawaz A ◽

◽

Shim I ◽

Tilley D ◽

Kelaney MR ◽

...

Keyword(s):

Clinical Trial ◽

Overall Survival ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Real World ◽

Systemic Therapy ◽

Kinase Inhibitor ◽

Advanced Soft Tissue Sarcoma ◽

Clinical Trial Setting ◽

Trial Setting

Background: Pazopanib is an oral multitarget tyrosine kinase inhibitor that is currently approved for the treatment of select subtypes of advanced Soft Tissue Sarcoma (STS) in patients who have progressed on prior anthracyclinebased chemotherapy regimens. In this study, we examine data from multiple centers to assess the efficacy of pazopanib in practice outside of a clinical trial setting. Methods: A retrospective chart analysis was conducted for pre-treated, advanced soft tissue sarcoma patients who began treatment with pazopanib in Alberta, Canada and Cairo, Egypt (2012-2018). Results: In total, 39 predominantly male (56.4%) patients received pazopanib. The median age was 51, 67% of whom had an ECOG of one or less. The predominant sarcoma subtype was leiomyosarcoma (30.8%), and all patients had received at least one prior line of systemic therapy. Thirtytwo of the 39 patients (82%) were initially given the full dose of 800mg with a median time on treatment of 116 days. Seven of the 39 (18%) patients required a dose reduction while on treatment. A majority (94.9%) of patients ultimately discontinued pazopanib treatment for reasons including death (21.6%), disease progression (62.2%), and toxicity (16.4%). The median progression-free and overall survival for these patients was 4.1 months (95%CI, 3.6-4.5) and 8.4 months (95% CI, 4.3-12.5), respectively. Conclusion: Pazopanib is an efficient and generally well-tolerated oral systemic therapy for the treatment of advanced, pre-treated, non-adipocytic soft tissue sarcoma. These results show the efficacy of pazoponib outside of a clinical trial setting.

Download Full-text